Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 188re-lanreotide
2. 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
3. 3-(2-naphthyl)-d-ala-cys-tyr-d-trp-lys-val-cys-thr-nh2
4. 3-(2-naphthyl)alanyl-cystinyl-tyrosyl-tryptophyl-lysyl-valyl-cystinyl-threonine Amide
5. Angiopeptin
6. Bim 23014
7. Bim 23014 C
8. Bim 23014c
9. Bim-23014
10. Bim-23014 C
11. D-nal-cys-tyr-trp-lys-val-cys-thr-nh2
12. Dc 13-116
13. Dc-13-116
14. Dc13-116
15. L-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, Cyclic (2-7)-disulfide
16. Lanreotide
17. Lanreotide Acetate
18. Lanreotide-sr
19. Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-nh2
20. Nal-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2
21. Naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
22. Naphthyl-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2
23. Somatulin
24. Somatulina
25. Somatuline
1. Somatuline Lp
2. Lanreotide (acetate)
3. Bim-23014c
4. Ipstyl
5. Somatuline
6. Somatuline Autogel
7. 2378114-72-6
8. Angiopeptin Acetate
9. Somatulina
10. Somatuline La
11. Acetic Acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
12. Chembl1201184
13. Hy-p1959a
14. Itm-014
15. Mfcd00873576
16. Bn-52030
17. Dc13-116
18. Cs-0113779
19. P1088
Molecular Weight | 1156.4 g/mol |
---|---|
Molecular Formula | C56H73N11O12S2 |
Hydrogen Bond Donor Count | 14 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 17 |
Exact Mass | 1155.48815915 g/mol |
Monoisotopic Mass | 1155.48815915 g/mol |
Topological Polar Surface Area | 443 Ų |
Heavy Atom Count | 81 |
Formal Charge | 0 |
Complexity | 2030 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Somatuline depot |
PubMed Health | Lanreotide (Subcutaneous) |
Drug Classes | Endocrine-Metabolic Agent |
Drug Label | Somatuline Depot (lanreotide) Injection 60, 90 and 120 mg is a prolonged-release formulation for deep subcutaneous injection containing the drug substance lanreotide acetate, a synthetic octapeptide with a biological activity similar to naturally occ... |
Active Ingredient | Lanreotide acetate |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | eq 90mg base; eq 120mg base; eq 60mg base |
Market Status | Prescription |
Company | Ipsen Pharma |
2 of 2 | |
---|---|
Drug Name | Somatuline depot |
PubMed Health | Lanreotide (Subcutaneous) |
Drug Classes | Endocrine-Metabolic Agent |
Drug Label | Somatuline Depot (lanreotide) Injection 60, 90 and 120 mg is a prolonged-release formulation for deep subcutaneous injection containing the drug substance lanreotide acetate, a synthetic octapeptide with a biological activity similar to naturally occ... |
Active Ingredient | Lanreotide acetate |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | eq 90mg base; eq 120mg base; eq 60mg base |
Market Status | Prescription |
Company | Ipsen Pharma |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : Complete
Rev. Date : 2020-04-03
Pay. Date : 2019-02-01
DMF Number : 33336
Submission : 2019-02-08
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39768
Submission : 2024-06-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24378
Submission : 2010-11-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39254
Submission : 2023-12-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39673
Submission : 2024-06-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8974
Submission : 1991-02-22
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-12-21
Pay. Date : 2015-09-15
DMF Number : 29693
Submission : 2016-08-16
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-02-13
Pay. Date : 2023-01-30
DMF Number : 36547
Submission : 2023-02-02
Status : Active
Type : II
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6272
Start Marketing Date : 2021-08-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6264
Start Marketing Date : 2019-10-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 35207-0011
Start Marketing Date : 2018-08-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 32861-0006
Start Marketing Date : 2017-12-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
About the Company : With more than 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology comp...
About the Company : Aspen API is the cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. With quality, compliance, and teamwork at its core, Aspen...
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
About the Company : Established in 1990, Inabata France, a part of the Inabata Group, used to export chemical and pharmaceutical products to Japan. In 2006, it acquired Pharmasynthèse. Today, Inabata...
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
About the Company : Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) offers global customers cost-effective APIs with speed, supported by our well-trained staff. As the first company in Southeast...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
About the Company : BCN Peptides is a privately own company completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications. We are a customer oriented...
About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...
About the Company : Shenzhen JYMed Technology Co.,Ltd is a high-tech enterprise engaged in research and development, manufacturing and commercialization of peptides based products, including active ph...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
38
PharmaCompass offers a list of Lanreotide Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lanreotide Acetate manufacturer or Lanreotide Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lanreotide Acetate manufacturer or Lanreotide Acetate supplier.
PharmaCompass also assists you with knowing the Lanreotide Acetate API Price utilized in the formulation of products. Lanreotide Acetate API Price is not always fixed or binding as the Lanreotide Acetate Price is obtained through a variety of data sources. The Lanreotide Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lanreotide Acetate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lanreotide Acetate, including repackagers and relabelers. The FDA regulates Lanreotide Acetate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lanreotide Acetate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lanreotide Acetate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lanreotide Acetate supplier is an individual or a company that provides Lanreotide Acetate active pharmaceutical ingredient (API) or Lanreotide Acetate finished formulations upon request. The Lanreotide Acetate suppliers may include Lanreotide Acetate API manufacturers, exporters, distributors and traders.
click here to find a list of Lanreotide Acetate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lanreotide Acetate DMF (Drug Master File) is a document detailing the whole manufacturing process of Lanreotide Acetate active pharmaceutical ingredient (API) in detail. Different forms of Lanreotide Acetate DMFs exist exist since differing nations have different regulations, such as Lanreotide Acetate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lanreotide Acetate DMF submitted to regulatory agencies in the US is known as a USDMF. Lanreotide Acetate USDMF includes data on Lanreotide Acetate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lanreotide Acetate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lanreotide Acetate suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lanreotide Acetate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lanreotide Acetate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lanreotide Acetate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lanreotide Acetate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lanreotide Acetate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lanreotide Acetate suppliers with NDC on PharmaCompass.
Lanreotide Acetate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lanreotide Acetate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lanreotide Acetate GMP manufacturer or Lanreotide Acetate GMP API supplier for your needs.
A Lanreotide Acetate CoA (Certificate of Analysis) is a formal document that attests to Lanreotide Acetate's compliance with Lanreotide Acetate specifications and serves as a tool for batch-level quality control.
Lanreotide Acetate CoA mostly includes findings from lab analyses of a specific batch. For each Lanreotide Acetate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lanreotide Acetate may be tested according to a variety of international standards, such as European Pharmacopoeia (Lanreotide Acetate EP), Lanreotide Acetate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lanreotide Acetate USP).